Irisin Skepticism Goes Way Back

Post-publication peer reviewers had questioned data about the supposed fat-browning enzyme from the get-go.

Written byKerry Grens
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WIKIMEDIA, HELLERHOFFA recent study in Scientific Reports this month (March 9) pointed to the existence of a fat browning protein called irisin as nothing more than “myth.” But as scientist Paul Brookes noted on Twitter today (March 18), “‘News on #Irisin being an artifact . . . will be no surprise to @PubPeer readers.”

PubPeer users have been scrutinizing the original 2012 Nature paper on irisin, by Bruce Spiegelman at Harvard Medical School and colleagues, since 2013, when Duke biochemist Harold Erickson penned a critical commentary on the study in Adipocyte. (Erickson went on to coauthor the recent Scientific Reports study.)

The PubPeer discussion initially focused on the antibody Spiegelman’s group used to detect irisin. A commenter who claims to be Spiegelman described how the antibody was “misannotated” by the company, but still detects the cleaved form of irisin. Following suggestions by other commenters, Spiegelman posted data supporting his conclusion.

Some were satisfied by Spiegelman’s efforts and applauded his follow-up, but others remained skeptical, particularly regarding the quality of reagents used in Spiegelman’s and others’ studies on irisin. One ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies